Opinicus Capital Inc. Acquires Shares of 1,241 Humana Inc. (NYSE:HUM)

Opinicus Capital Inc. acquired a new stake in Humana Inc. (NYSE:HUM) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 1,241 shares of the insurance provider’s stock, valued at approximately $568,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Rakuten Securities Inc. acquired a new position in shares of Humana during the 4th quarter worth $25,000. Gradient Investments LLC raised its holdings in shares of Humana by 200.0% during the 4th quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock worth $27,000 after buying an additional 40 shares in the last quarter. Cetera Trust Company N.A acquired a new position in shares of Humana during the 4th quarter worth $28,000. Nvwm LLC increased its holdings in Humana by 41.0% in the 3rd quarter. Nvwm LLC now owns 86 shares of the insurance provider’s stock worth $42,000 after purchasing an additional 25 shares in the last quarter. Finally, Operose Advisors LLC acquired a new position in Humana in the 3rd quarter worth about $56,000. 92.38% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on HUM. TD Cowen lowered their target price on Humana from $427.00 to $396.00 and set a “buy” rating for the company in a report on Tuesday, April 2nd. TheStreet cut Humana from a “b” rating to a “c+” rating in a report on Monday, January 8th. Jefferies Financial Group lowered their target price on Humana from $411.00 to $381.00 and set a “buy” rating for the company in a report on Monday, April 22nd. Cantor Fitzgerald lowered their target price on Humana from $391.00 to $360.00 and set a “neutral” rating for the company in a report on Thursday. Finally, Royal Bank of Canada lowered their target price on Humana from $415.00 to $353.00 and set an “outperform” rating for the company in a report on Thursday. Eleven research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, Humana has an average rating of “Hold” and a consensus price target of $433.74.

Humana Trading Down 1.8 %

Shares of Humana stock traded down $5.51 on Friday, hitting $305.90. 1,213,131 shares of the company’s stock traded hands, compared to its average volume of 1,914,716. Humana Inc. has a one year low of $299.23 and a one year high of $541.21. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.67 and a quick ratio of 1.59. The company has a fifty day moving average of $327.77 and a two-hundred day moving average of $394.49. The company has a market capitalization of $36.86 billion, a price-to-earnings ratio of 19.05, a price-to-earnings-growth ratio of 1.82 and a beta of 0.45.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 EPS for the quarter, beating the consensus estimate of $6.12 by $1.11. Humana had a return on equity of 17.76% and a net margin of 1.82%. The company had revenue of $29.61 billion for the quarter, compared to analyst estimates of $28.52 billion. During the same quarter in the prior year, the company earned $9.38 EPS. The firm’s revenue for the quarter was up 10.7% compared to the same quarter last year. As a group, sell-side analysts expect that Humana Inc. will post 16.07 earnings per share for the current year.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a $0.885 dividend. The ex-dividend date is Friday, June 28th. This represents a $3.54 annualized dividend and a yield of 1.16%. Humana’s payout ratio is currently 22.04%.

Insiders Place Their Bets

In other news, Director Jorge S. Mesquita purchased 545 shares of the business’s stock in a transaction on Tuesday, February 20th. The shares were acquired at an average price of $367.09 per share, for a total transaction of $200,064.05. Following the completion of the acquisition, the director now owns 2,578 shares in the company, valued at $946,358.02. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.32% of the company’s stock.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.